3D bioprinting company Organovo entered into a research collaboration agreement with L’Oreal USA to develop skin tissue models using Organovo’s NovoGen Bioprinter.
While L’Oreal will have the exclusive right to use the 3D printed skin tissue for the development, manufacturing, testing, evaluation and sale of non-prescription cosmetic and skin care products, Organovo retains the right to use it for toxicity testing of prescription drugs and for developing and testing surgically transplanted and therapeutic tissues.
The three phases of the research agreement include development, validation and commercial supply, with the first two phases requiring L’Oreal to make upfront payments for certain deliverables. Reaching phase 3, the two parties will negotiate an exclusive commercial supply agreement, including licensing and royalty terms.
Only recently we have reported on Organovo’s presentation of its first fully cellular 3D printed kidney tissue, which is also printed on the company’s proprietary NovoGen bioprinting platform.